NeuroOne to Showcase OneRF Trigeminal Nerve Ablation System and SEEG Drug Delivery Platform at ASSFN Biennial Meeting

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced its participation in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Biennial Meeting, taking place May 30–June 2 at the Hilton Cleveland Downtown. The company will present its recently 510(k)-cleared OneRF Trigeminal Nerve Ablation System and provide updates on its investigational SEEG-Drug Delivery System, underscoring its commitment to advancing surgical options for neurological disorders.

The OneRF Trigeminal Nerve Ablation System, cleared under K251243, is designed for creating radiofrequency lesions to treat chronic facial pain or for functional neurosurgical procedures. Its multi-contact RF probe enables precise mapping and ablation without repositioning, potentially reducing procedural time and improving patient comfort. NeuroOne recently completed the limited market release of this system, marking a significant step toward broader clinical adoption.

In addition, NeuroOne will share details on its SEEG-Drug Delivery System, currently under development for investigational studies. This device aims to integrate drug delivery, recording, and stimulation capabilities through a single implant, supporting multiple trajectories and repeated dosing. While not yet approved by the FDA, the system represents a potential advance in combining diagnostic and therapeutic functions for neurological conditions.

At the conference, NeuroOne will deliver a scientific presentation titled "Integrating Drug Delivery Capabilities into a SEEG-Based Recording, Stimulation, and Ablation Platform Technology" on May 31 from 3:40–6:00 PM ET. The company will also present two posters: "SEEG-Guided Radiofrequency Ablation with Real-Time Temperature Control: From Early Clinical Experience to the Development of a Post-Market Registry" and "New FDA-cleared Multi-Contact RF Probe for Trigeminal Neuralgia: Cadaveric Feasibility and Usability Evaluation." Multiple neurosurgeons will also present their clinical experiences with both the OneRF Radiofrequency Ablation System (brain) and the Trigeminal Nerve Ablation System.

The presentations highlight NeuroOne's focus on expanding its electrode technology platform, which includes four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (brain), and the new Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and improve outcomes by offering diagnostic and therapeutic functions in a minimally invasive format.

NeuroOne continues to engage in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. For more information about the company and its technologies, visit nmtc1.com.